Valeant Pharmaceuticals International Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 2 Calls Today's Calls

Call Details Valeant Pharmaceuticals International Earnings Conference Call (Q3 2009) Mon, Nov 2, 2009, 10:00 am Eastern Listen to the archived event audio About Valeant Pharmaceuticals International (NYSE:VRX) Valeant Pharmaceuticals International, a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of pharmaceutical products. It primarily offers specialty pharmaceutical and over-the-counter (OTC) products in the areas of dermatology and neurology therapeutic classes. The company’s products include Efudex/Efudix for the treatment of multiple actinic or solar keratoses and superficial basal cell carcinoma; Diastat/Diastat AcuDial, which are gel formulations of diazepam; Cesamet, a synthetic cannabinoid used for the management of severe nausea and vomiting; Bedoyecta, a brand of vitamin B complex; Bisocard to treat hypertension and angina pectoris; and Kinerase, a range of OTC and prescription cosmetic products. It also offers Mestinon, an orally active cholinesterase inhibitor used in the treatment of myasthenia gravis; M.V.I., a hospital dietary supplement used in treating trauma and burns; Migranal, a nasal spray formulation for the treatment of acute migraine headaches; Nyal to treat cough, cold, flu, sinus, and hayfever symptoms; and Virazole for the treatment of hospitalized infants and young children with lower respiratory tract infections. As of December 31, 2008, its product portfolio comprised approximately 389 products, with approximately 982 stock keeping units. The company markets its pharmaceutical products to physicians, hospitals, pharmacies, and wholesalers through its sales force, as well as through wholesalers in the United States, Mexico, Poland, and Canada. It has a collaboration agreement with Glaxo Group Limited to develop and commercialize retigabine, a neuronal potassium channel opener for the treatment of adult epilepsy patients with refractory partial onset seizures. Valeant Pharmaceuticals was founded in 1960 and is headquartered in Aliso Viejo, California. More Info: Quote | Chart | News | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings